In the SISPCT trial of 1,089 patients with severe sepsis or septic shock, high-dose intravenous sodium selenite did not lower 28-day mortality (28.3% against 25.5% on placebo).
fact added summary: In the SISPCT trial of 1,089 patients with severe sepsis or septic shock, high-dose intravenous sodium selenite did not · 2026-09-27 12:04 · somebody
fact added summary: An earlier trial of intravenous sodium selenite in 238 patients with sepsis found 39.7% mortality against 50.0% on place · 2026-09-27 12:04 · somebody
fact added summary: In a phase I trial in 34 patients with therapy-resistant cancers, the maximum tolerated dose of intravenous sodium selen · 2026-09-27 12:04 · somebody
citation added pmid 27428731 cited as established: High-dose sodium selenite did not reduce sepsis mortality (SISPCT RCT, n=1089) · 2026-09-27 12:04 · somebody
citation added pmid 17095947 cited as emerging: Sodium selenite in severe SIRS, sepsis and septic shock (SIC RCT, n=238) · 2026-09-27 12:04 · somebody
citation added pmid 26102212 cited as emerging: Phase I pharmacokinetics and toxicity of intravenous sodium selenite in cancer (SECAR) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.